Drug Trial Radar · NCT03047395
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Last checked: Nov 20, 2026Latest source record: Dec 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,170
Actual
Start
Feb 27, 2017
Primary completion
Nov 29, 2023
Study completion Nov 29, 2023
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
Conditions
- Psoriasis
Interventions
risankizumabBiological
Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Serious Adverse Events and Non-Serious Adverse EventsTime frame: Median follow-up time of 1905 days
Locations
233 sites in 17 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center /ID# 154000
Birmingham, Alabama
University of Alabama at Birmingham - Main /ID# 153983
Birmingham, Alabama
NW Arkansas Clinical Trials Center /ID# 154014
Rogers, Arkansas
Bakersfield Derma & Skin Cance /ID# 154008
Bakersfield, California
California Dermatology and Research Institute /ID# 154007
Encinitas, California
T. Joseph Raoof, MD, Inc. /ID# 154078
Encino, California
Center for Dermatology Clinical Research /ID# 154009
Fremont, California
Kaiser Permanente Los Angeles /ID# 154079
Los Angeles, California
Dermatology Research Associates /ID# 153977
Los Angeles, California
Wallace Medical Group /ID# 154025
Los Angeles, California
Dermatology Specialists, Inc /ID# 153984
Oceanside, California
Huntington Medical Foundation /ID# 154002
Pasadena, California
Medderm Associates /ID# 154098
San Diego, California
Southern California Dermatology /ID# 154006
Santa Ana, California
UNISON Center for Clinical Tri /ID# 153979
Sherman Oaks, California
New England Research Associates, LLC /ID# 154004
Bridgeport, Connecticut
UConn Health /ID# 154128
Farmington, Connecticut
Florida Academic Centers Research /ID# 154045
Coral Gables, Florida
Leavitt Medical Associates of Florida /ID# 154046
Ormond Beach, Florida
Progressive Medical Research /ID# 154027
Port Orange, Florida
Hamilton Research, LLC /ID# 153980
Alpharetta, Georgia
Advanced Medical Research, PC /ID# 153999
Sandy Springs, Georgia
Northwestern University Feinberg School of Medicine /ID# 153974
Chicago, Illinois
Rush University Medical Center /ID# 154099
Chicago, Illinois
Arlington Dermatology /ID# 153975
Rolling Meadows, Illinois
Northshore University Health System Dermatology Clinical Trials Unit /ID# 154011
Skokie, Illinois
Dundee Dermatology /ID# 154110
West Dundee, Illinois
Dawes Fretzin, LLC /ID# 154146
Indianapolis, Indiana
The Dermatology Center PSC - New Albany /ID# 154075
New Albany, Indiana
The Indiana Clinical Trials Center /ID# 153976
Plainfield, Indiana
The South Bend Clinic Center /ID# 154147
South Bend, Indiana
Epiphany Dermatology of Kansas LLC /ID# 153993
Overland Park, Kansas
Skin Sciences, PLLC /ID# 153991
Louisville, Kentucky
DS Research /ID# 154028
Louisville, Kentucky
Massachusetts General Hospital /ID# 153990
Boston, Massachusetts
ActivMed Practices and Research, LLC. /ID# 154044
Methuen, Massachusetts
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 154111
Ann Arbor, Michigan
Great Lakes Research Group - Bay City /ID# 153998
Bay City, Michigan
Michigan Center for Skin Care Research /ID# 153986
Clinton Township, Michigan
Somerset Skin Centre /ID# 154097
Troy, Michigan
Showing 40 of 233 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.